SCOTTS MIRACLE-GRO CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SCOTTS MIRACLE-GRO CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Sep 30, 2015 | $3.02B | Nov 24, 2015 |
| FY2015 | Sep 30, 2014 | $2.84B | Nov 24, 2015 |
| FY2015 | Sep 30, 2013 | $2.77B | Nov 24, 2015 |
| FY2014 | Sep 30, 2012 | $2.77B | Nov 25, 2014 |
| FY2013 | Sep 30, 2011 | $2.80B | Nov 20, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.41B | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $3.55B | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $3.55B | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $3.92B | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $4.93B | Nov 22, 2023 |
| FY2020 | Sep 30, 2020 | $890.30M | Nov 24, 2020 |
| FY2020 | Jun 27, 2020 | $1.49B | Nov 24, 2020 |
| FY2020 | Mar 28, 2020 | $1.38B | Nov 24, 2020 |
| FY2020 | Dec 28, 2019 | $365.80M | Nov 24, 2020 |
| FY2020 | Sep 30, 2019 | $497.70M | Nov 24, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $376.70M | Nov 28, 2017 |
| FY2017 | Jul 1, 2017 | $973.40M | Nov 28, 2017 |
| FY2017 | Apr 1, 2017 | $1.08B | Nov 28, 2017 |
| FY2017 | Dec 31, 2016 | $207.40M | Nov 28, 2017 |
| FY2017 | Sep 30, 2016 | $348.70M | Nov 28, 2017 |
| FY2017 | Jul 2, 2016 | $887.10M | Nov 28, 2017 |
| FY2017 | Apr 2, 2016 | $1.12B | Nov 28, 2017 |
| FY2017 | Jan 2, 2016 | $153.00M | Nov 28, 2017 |
| FY2016 | Sep 30, 2015 | $375.40M | Nov 28, 2016 |
| FY2016 | Jun 27, 2015 | $1.11B | Nov 28, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.04B | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $850.50M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $657.30M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $872.90M | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $1.47B | Nov 22, 2023 |
| FY2020 | Sep 30, 2020 | $216.00M | Nov 24, 2020 |
| FY2020 | Jun 27, 2020 | $526.70M | Nov 24, 2020 |
| FY2020 | Mar 28, 2020 | $550.20M | Nov 24, 2020 |
| FY2020 | Dec 28, 2019 | $54.20M | Nov 24, 2020 |
| FY2020 | Sep 30, 2019 | $89.50M | Nov 24, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $145.20M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($34.90M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($380.10M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | ($437.50M) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $512.50M | Nov 22, 2023 |
| FY2020 | Sep 30, 2020 | $3.90M | Nov 24, 2020 |
| FY2020 | Jun 27, 2020 | $202.80M | Nov 24, 2020 |
| FY2020 | Mar 28, 2020 | $252.20M | Nov 24, 2020 |
| FY2020 | Dec 28, 2019 | ($71.40M) | Nov 24, 2020 |
| FY2020 | Sep 30, 2019 | ($57.90M) | Nov 24, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $358.60M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $208.80M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($174.40M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | ($434.00M) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $723.00M | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $585.20M | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $409.60M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $198.90M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $433.40M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $447.60M | Nov 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $34.80M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $34.60M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $35.70M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $45.30M | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $45.40M | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $39.70M | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $39.60M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $42.50M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $39.90M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $36.00M | Nov 29, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $603.40M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $559.00M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $551.30M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $613.00M | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $743.50M | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $757.80M | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $601.30M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $540.10M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $550.90M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $518.00M | Nov 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $371.30M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $667.50M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $531.00M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | ($129.00M) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $271.50M | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $558.00M | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $226.80M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $342.50M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $363.20M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $244.00M | Nov 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $97.40M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $84.00M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $92.80M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $113.50M | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $106.90M | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $62.70M | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $42.40M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $68.20M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $69.60M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $58.30M | Nov 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.74B | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $2.87B | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $3.41B | Nov 26, 2024 |
| FY2023 | Sep 30, 2022 | $4.30B | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | $4.80B | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | $3.38B | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $3.03B | Nov 24, 2020 |
| FY2019 | Sep 30, 2018 | $3.05B | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $2.75B | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $2.76B | Nov 28, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.10B | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $3.26B | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $3.68B | Nov 26, 2024 |
| FY2023 | Sep 30, 2022 | $4.15B | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | $3.79B | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | $2.68B | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $2.31B | Nov 24, 2020 |
| FY2019 | Sep 30, 2018 | $2.69B | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $2.09B | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $2.02B | Nov 28, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $1.01B | Nov 23, 2021 |
| FY2021 | Sep 30, 2020 | $697.20M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $718.70M | Nov 24, 2020 |
| FY2019 | Sep 30, 2018 | $354.60M | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $648.80M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $715.20M | Nov 28, 2017 |
| FY2016 | Sep 30, 2015 | $620.70M | Nov 28, 2016 |
| FY2015 | Sep 30, 2014 | $553.70M | Nov 24, 2015 |
| FY2014 | Sep 30, 2013 | $710.50M | Nov 25, 2014 |
| FY2013 | Sep 30, 2012 | $601.90M | Nov 20, 2013 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $243.90M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $243.90M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $243.90M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $254.00M | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $605.20M | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $544.10M | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $538.70M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $543.00M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $441.60M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $371.90M | Nov 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $294.70M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $303.80M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $490.90M | Nov 26, 2024 |
| FY2023 | Sep 30, 2022 | $1.02B | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | $1.61B | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | $1.24B | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $1.27B | Nov 24, 2020 |
| FY2019 | Sep 30, 2018 | $919.90M | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | $978.20M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | $881.80M | Nov 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $36.60M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $71.60M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $31.90M | Nov 26, 2024 |
| FY2023 | Sep 30, 2022 | $86.80M | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | $244.10M | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | $16.60M | Nov 23, 2021 |
| FY2020 | Sep 30, 2019 | $18.80M | Nov 24, 2020 |
| FY2019 | Sep 30, 2018 | $33.90M | Nov 27, 2019 |
| FY2019 | Sep 30, 2017 | $120.50M | Nov 27, 2019 |
| FY2019 | Sep 30, 2016 | $28.60M | Nov 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.11B | Nov 25, 2025 |
| FY2024 | Sep 30, 2024 | $2.23B | Nov 26, 2024 |
| FY2023 | Sep 30, 2023 | $2.61B | Nov 22, 2023 |
| FY2022 | Sep 30, 2022 | $2.96B | Nov 28, 2022 |
| FY2021 | Sep 30, 2021 | $2.28B | Nov 23, 2021 |
| FY2020 | Sep 30, 2020 | $1.50B | Nov 24, 2020 |
| FY2019 | Sep 30, 2019 | $1.63B | Nov 27, 2019 |
| FY2018 | Sep 30, 2018 | $2.03B | Nov 29, 2018 |
| FY2017 | Sep 30, 2017 | $1.41B | Nov 28, 2017 |
| FY2017 | Sep 30, 2016 | $1.22B | Nov 28, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 2 | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | (6) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | (7) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | 9 | Nov 22, 2023 |
| FY2020 | Sep 30, 2020 | 0 | Nov 24, 2020 |
| FY2020 | Jun 27, 2020 | 3 | Nov 24, 2020 |
| FY2020 | Mar 28, 2020 | 4 | Nov 24, 2020 |
| FY2020 | Dec 28, 2019 | (1) | Nov 24, 2020 |
| FY2020 | Sep 30, 2019 | (1) | Nov 24, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 2 | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | (6) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | (7) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | 8 | Nov 22, 2023 |
| FY2020 | Sep 30, 2020 | 0 | Nov 24, 2020 |
| FY2020 | Jun 27, 2020 | 3 | Nov 24, 2020 |
| FY2020 | Mar 28, 2020 | 4 | Nov 24, 2020 |
| FY2020 | Dec 28, 2019 | (1) | Nov 24, 2020 |
| FY2020 | Sep 30, 2019 | (1) | Nov 24, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 57.80M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 57.10M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | 56.50M | Nov 26, 2024 |
| FY2023 | Sep 30, 2022 | 55.50M | Nov 22, 2023 |
| FY2022 | Sep 30, 2021 | 55.60M | Nov 28, 2022 |
| FY2019 | Sep 30, 2019 | 55.80M | Nov 27, 2019 |
| FY2019 | Sep 30, 2018 | 55.30M | Nov 27, 2019 |
| FY2018 | Sep 30, 2017 | 58.10M | Nov 29, 2018 |
| FY2017 | Sep 30, 2016 | 60.30M | Nov 28, 2017 |
| FY2016 | Sep 30, 2015 | 61.40M | Nov 28, 2016 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $154.30M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $151.30M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $149.10M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $166.20M | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $143.00M | Nov 22, 2023 |
| FY2022 | Sep 30, 2020 | $411.20M | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $124.50M | Nov 23, 2021 |
| FY2020 | Sep 30, 2018 | $120.00M | Nov 24, 2020 |
| FY2019 | Sep 30, 2017 | $120.30M | Nov 27, 2019 |
| FY2018 | Sep 30, 2016 | $116.60M | Nov 29, 2018 |